



Assoc. Prof. Filip Janku M.D., Ph.D.

University of Texas Health Science Center
Houston Graduate School of Biomedical
Sciences, Houston

Dr. Janku is an Assistant Professor in the Department of Investigational Cancer Therapeutics (Phase I Program) at MD Anderson Cancer Center. He completed a medical oncology fellowship in 2005, and then served as a consultant medical oncologist in Ireland for three years. Before coming to MD Anderson, he served as a Principal Investigator for numerous research studies and received several grants to support the development of a Clinical Trials Program. In September 2007, he earned his Ph.D. degree in biochemistry. From February 2009 to February 2011, he was a fellow in the Department of Investigational Cancer Therapeutics where he gained invaluable experience in using molecularly targeted therapeutics and early drug development. Since joining the Department of Investigational Cancer Therapeutics in 2011, he has written several phase I protocols, which are currently accruing patients. In addition, he is a PI for several first-in-human/first-in-class clinical studies. This department currently has more than 100 phase I trials on its priority list, most of which involve novel, targeted agents, several of those being first-in-human studies. He received multiple awards for his research efforts, including four Merit Awards from ASCO as well as an AACR Scholar-in-Training Award. He has published 63 articles in highly respected, peer-reviewed journals. He has a long-standing interest in molecular factors underlying sensitivity or resistance to cancer therapies. He has a strong track record in translational research and, if successful, he is prepared to translate his research to patient care.

Positions and Employment

- | | |
|--------------|---|
| 2003–2005 | Assistant Professor, Department of Oncology, Charles University Prague, First Faculty of Medicine |
| 2005–present | Consultant Medical Oncologist, St. James Hospital, University Teaching Hospital of Trinity College Dublin, Ireland |
| 2006–2009 | Consultant Medical Oncologist, Cancer Services, Bon Secours Hospital, Cork, Ireland, Cork |
| 2006–2009 | Senior Lecturer, University College, Cork |
| 2011–present | Assistant Professor, Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center (MD Anderson), Houston, TX |
| 2012–present | Associate Member, The University of Texas Health Science Center Houston Graduate School of Biomedical Sciences, Houston, TX |

Other Experience and Professional Memberships

- | | |
|-----------|---|
| 2006–2009 | Transfusion Committee, Bon Secours Hospital |
| 2007–2009 | Ethical Committee, Bon Secours Hospital |
| 2008–2009 | Drug and Therapeutics Committee, Bon Secours Hospital |
| 2008–2009 | Ethical Committee, University College |
| 2010–2011 | Molecular Testing Evaluation Committee, MD Anderson |



- 2011–present Clinical Trials Committee,
Irish Medicines Board
- 2011–present CTS Steering Committee, MD Anderson
- 2012–2013 Medical Practice Committee, MD Anderson
- 2013–present Clinical Research Committee,
MD Anderson
- 2015–present Institutional Review Board, MD Anderson

Honors

- 2003 Merit Award, American Society of
Clinical Oncology (ASCO) Annual Meeting
- 2010 Merit Award, ASCO Annual Meeting
- 2010 Bristol-Myers Squibb Award,
Clinical/Translational Research
- 2010 Merit Award, ASCO, ASCO-NCI-EORTC
Meeting on Molecular Markers
- 2011 AACR Scholar-in-Training Award,
AACR Conference on Targeting
PI3K/mTOR Signaling
- 2011 Merit Award, ASCO Annual Meeting
- 2014 Kimmel Award, Kimmel Foundation

Contribution to Science

Dr. Janku demonstrated that therapeutic matching with PI3K/mTOR inhibitors in patients with advanced cancers and PIK3CA or PTEN aberrations can lead to increased

response in early phase clinical trials compared to patients treated without therapeutic matching. This work has been published in most prestigious journals such as *Journal of Clinical Oncology*, *Cell Reports*, *Cancer Research* and *Molecular Cancer Therapeutics*. His contribution to the field was recognized at the national and international level and he is leading as a national PI the NCI MATCH clinical trial arms targeting PTEN aberrant cancers.

Dr. Janku has been systematically working to develop a liquid biopsies program. He demonstrated that liquid biopsies can be used in lieu of tumor tissue for molecular profiling in cancer to determine molecular targets, response to therapy, prognosis and clonal evolution.

He had a key role in a development of an oncolytic bacteria *clostridium novyi-NT*, which has significant activity in variety of cancers with significant level of hypoxia. Complete List of Published Work in his Bibliography: <https://www.ncbi.nlm.nih.gov/myncbi/filip.janku.1/bibliography/48519896/public/>

Research Support and/or Scholastic Performance

Dr. Janku has a role of Principal Investigator in 15 ongoing and 3 completed studies.